Inhibrx Biosciences, Inc. INBX Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s change in accrued liabilities?
- Inhibrx Biosciences, Inc. (INBX) reported change in accrued liabilities of -$10.19M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s change in accrued liabilities changed year-over-year?
- Inhibrx Biosciences, Inc.'s change in accrued liabilities decreased by 453.2% year-over-year, from $2.88M to -$10.19M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.